Results {#s1}
=======

It has recently been discovered that the immune receptor Tim-3 (T cell immunoglobulin and mucin domain-containing protein 3) and it\'s ligand galectin-9 determines the capability of various types of malignant cells \[e.g., acute myeloid leukemia (AML), colorectal cancer\] to escape host immune surveillance (Kang et al., [@B3]; Gonçalves Silva et al., [@B2]; Sakhnevych et al., [@B7]; Yasinska et al., [@B10]). Also, some of the galectin family members (for example galectin-3) were found to be able to protect AML and colorectal cancer cells against apoptosis through mitochondrial stabilization in a B cell lymphoma protein (Bcl) 2-dependent manner (Lee et al., [@B4]; Ruvolo, [@B6]). We asked whether galectin-9 has the same intracellular anti-apoptotic activity in addition to its extracellular immunosuppressive role. We used a pharmacological inhibitor 5-\[(4-bromophenyl)methylene\]-a-(1-methylethyl)-4-oxo-2-thioxo-3-thiazolidineacetic acid (BH3I-1, [Figure 1A](#F1){ref-type="fig"}), a synthetic cell permeable Bcl-X~L~ antagonist, which induces apoptosis via inhibition of interactions between the BH3 domain and Bcl-X~L~ thus defunctionalyzing mitochondria. We found that BH3I-1 was capable of inducing apoptosis in Colo 205 colorectal adenocarcinoma cells of epithelial origin (based on increased caspase-3 activity and decreased viability of the cells, [Figure 1A](#F1){ref-type="fig"}). Silencing either galectin-9 or its receptor and possible trafficker Tim-3 did not affect the pro-apoptotic activity of BH3I-1 suggesting that galectin-9 is unlikely to display anti-apoptotic activity in this case. Interestingly, the action of BH3I-1 did not affect the activity of mammalian target of rapamycin (mTOR) translational pathway as seen from its capability to phosphorylate eukaryotic initiation factor-4E-binding protein (eIF4E-BP, [Figure 1B](#F1){ref-type="fig"}). Obviously, one could suggest that Colo 205 cells accumulate galectin-9 on their surface and inside the cells based on FACS analysis ([Figure 1C](#F1){ref-type="fig"}). Reduced levels of surface-based Tim-3 might indicate its masking by galectin-9 (Yasinska et al., [@B9]). BH3I-1 does not affect the ability of Colo 205 cells to secrete galectin-9 ([Figure 1D](#F1){ref-type="fig"}) but significantly reduces its surface presence ([Figure 1E](#F1){ref-type="fig"}) as measured by on-cell assay. Colo 205 cells accumulate the Tim-3-galectin-9 complex ([Figure 1F](#F1){ref-type="fig"}) at a level comparable to THP-1 AML cells (K562 chronic ML cells expressing traces of galectin-9 were used as a negative control). Both proteins are also clearly detectable in Colo 205 cells by Western blot ([Figure 1G](#F1){ref-type="fig"}) and treatment with BH3I-1 reduces intracellular levels of galectin-9. Importantly, Western blot analysis of Colo 205 mitochondrial extracts showed that the Tim-3-galectin-9 complex is accumulated in mitochondria upon stimulation with BH3I-1 ([Figure 1H](#F1){ref-type="fig"}). The intracellular levels of galectin-9 mRNA were significantly reduced upon stimulation with BH3I-1, as detected by quantitative real-time PCR (qRT-PCR, [Figure 1I](#F1){ref-type="fig"}).

![Pro-apoptotic defunctionalization of mitochondria reduces galectin-9 expression and leads to its redistribution in human Colo 205 colorectal adenocarcinoma cells. Colo 205 cells were exposed to 100 μM BH3I-1 for 24 h followed by **(A)** detection of cell viability using an MTS test and colorimetric assay of caspase-3 activity. Cell viability was also tested for normal and Tim-3 or galectin-9 knockdown Colo 205 cells. **(B)** Following 24 h of exposure to BH3I-1 S65-phosphorylation levels of eIF4E-BP were analyzed by Western blot. **(C)** Surface presence and total cellular levels of Tim-3 and galectin-9 were analyzed in Colo 205 cells using FACS. **(D)** Secreted levels of galectin-9 were analyzed in Colo 205 cells following 24 h of exposure to BH3I-1 by ELISA. **(E)** Surface levels of galectin-9 in non-treated and BH3I-1-stimulated Colo 205 cells were compared using an on-cell assay. **(F)** The presence of Tim-3-galectin-9 complex in Colo 205 cells was confirmed using Western blot analysis (bands were appearing at around 70 KDa, better detectable when temperature denaturation is not applied). THP-1 cells were used as a positive and K562 as a negative control. **(G)** Levels of Tim-3 and galectin-9 were analyzed in Colo 205 lysates following 24 h of exposure to BH3I-1 by Western blot. **(H)** Mitochondrial extracts were obtained from non-treated and BH3I-1-stimulated Colo 205 cells and subjected to Western blot analysis to detect Tim-3 and galectin-9. Total protein levels were measured using a Bradford assay and equal protein amounts were loaded onto the gels. **(I)** Galectin-9 mRNA levels were analyzed in non-treated Colo 205 cells and those exposed to BH3I-1 using qRT-PCR. In the scheme galectin-9 is abbreviated as G9. Quantitative results are shown as mean values (crucial mean values are written inside respective bars) ± SEM of 3--6 independent experiments. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001 vs. control. The scheme in the centre of the figure is based on our work on Tim-3-galectin-9 secretory pathway (Gonçalves Silva et al., [@B2]).](fphar-10-00342-g0001){#F1}

Interestingly, the ability of Colo 205 cells to secrete galectin-9 is lower compared to THP-1 AML cells and the levels of secretion in both cell types are proportional to cellular Tim-3 levels ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). This further supports conclusion regarding the involvement of Tim-3 in galectin-9 secretion (Gonçalves Silva et al., [@B2]).

We have also investigated two other types of epithelial cells---non-malignant human kidney RC-124 and malignant human HepG2 hepatoma cells. Both cell types have abundant mitochondria, however they are often \[especially non-malignant, like RC-124---confirmed by a direct chemical measurement as described of the drug-associated bromine (Sollo et al., [@B8]) uptake in these cells, data not shown\] less permeable for inhibitors of this type compared to colorectal cancer and AML cells. Therefore, 6 h of exposure to 1 mM H~2~O~2~ was used in order to defunctionalize mitochondria (Nicholas et al., [@B5]). We found that galectin-9 levels were significantly reduced in both cell types but the Tim-3-galectin-9 complex was only accumulated in the mitochondria of HepG2 and not RC-124 cells ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}).

Materials and Methods {#s2}
=====================

Commercially available Colo 205, RC-124, HepG2, THP-1, and K562, accompanied by authentication certificates, were used in this study. Mitochondria isolation, Western blot, on-cell assays, qRT-PCR, ELISA, and FACS analysis were performed as described before (Nicholas et al., [@B5]; Gonçalves Silva et al., [@B1], [@B2]; Yasinska et al., [@B9]). Detailed description of materials and methods used is provided in [Supplementary Information](#SM1){ref-type="supplementary-material"}.

Discussion {#s3}
==========

Our results indicate that colorectal cancer cells operate the Tim-3-galectin-9 secretory pathway, where Tim-3 acts as a galectin-9 binding partner and possible trafficker. Pro-apoptotic mitochondrial dysfunction leads to a decreased transcription of galectin-9 mRNA leading to its reduced translation. However, exocytosis of galectin-9 is affected by mitochondrial defunctionalization leading to a re-distribution of the Tim-3-galectin-9 complex into mitochondria where galectin-9 could possibly interact with mitochondrial glycoproteins. The physiological relevance of this process is unclear but may well be a part of the regulated cell suicide programme which might involve transfer of galectin-9 into mitochondria so that it can\'t be involved in protection of a dying cell thus allowing its smooth elimination. Our further studies indicate that this phenomenon might be applicable mainly to malignant epithelial cells ([Figure 1](#F1){ref-type="fig"}, [Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). Importantly, targeted defunctionalization of mitochondria in malignant cells may be a novel strategy for anti-cancer immunotherapy since it reduces cell surface presence of galectin-9 capable of suppressing anti-cancer activity of cytotoxic lymphoid cells.
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